EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Emtricitabine And Tenofovir Disoproxil Fumarate, and when can generic versions of Emtricitabine And Tenofovir Disoproxil Fumarate launch?
Emtricitabine And Tenofovir Disoproxil Fumarate is a drug marketed by Amneal Pharms Co, Apotex, Aurobindo Pharma, Aurobindo Pharma Ltd, Cipla, Laurus, Lupin Ltd, Macleods Pharms Ltd, Mylan, Strides Pharma, Teva Pharms Usa, and Zydus Pharms. and is included in twelve NDAs.
The generic ingredient in EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emtricitabine And Tenofovir Disoproxil Fumarate
A generic version of EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE was approved as emtricitabine; tenofovir disoproxil fumarate by TEVA PHARMS USA on June 8th, 2017.
Summary for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
| US Patents: | 0 |
| Applicants: | 12 |
| NDAs: | 12 |
| Finished Product Suppliers / Packagers: | 27 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Clinical Trials: | 176 |
| Patent Applications: | 203 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE at DailyMed |
Recent Clinical Trials for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Chiang Mai University, Thailand | Phase 3 |
| Assistance Publique - Hôpitaux de Paris, FRANCE | Phase 3 |
| Ministry of Health, Thailand | Phase 3 |
See all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE clinical trials
Pharmacology for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
Anatomical Therapeutic Chemical (ATC) Classes for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
US Patents and Regulatory Information for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharms Co | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 209721-001 | Aug 22, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Zydus Pharms | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 212689-003 | Jul 1, 2021 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Aurobindo Pharma Ltd | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 211640-001 | Mar 9, 2023 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Amneal Pharms Co | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 209721-004 | Aug 22, 2018 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
